About Curium Pharma (India) Private Limited
Data last updated:
Curium Pharma (India) Private Limited is a private limited company based in Mumbai, Maharashtra, India, a subsidiary of Iba Pharma Investments Sa (Belgium). It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 24 December 2004 and has been in existence for over 22 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24230MH2004PTC150212. Its GSTIN is 09AABCI3249R1ZZ (Uttar Pradesh). The company holds 3 GST registrations, of which 2 are active.
The company has an authorised share capital of ₹10.3 Cr and a paid-up capital of ₹10.3 Cr. It is led by directors including Xavier Anne J Defourt and Susamoy Mishra.
Its last annual general meeting (AGM) was held on 22 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 4/42 Tardeo A/C Market Building Tardeo Road, Mumbai, Maharashtra, India – 400034.
As per the financials filed for FY 2025, the company reported a revenue of ₹41.38 Cr, a decline of 3% compared to the previous year. For the same year it recorded a net profit of ₹4.53 Cr (net margin 11%) and EBITDA of ₹7.31 Cr (EBITDA margin 17.7%). Revenue has grown at a compounded annual rate (CAGR) of 9% over three years and 12% over five years.
The company has about 26 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: IBA. Court records list 3 cases involving the company, including 2 filed by the company and 1 filed against it; 1 case is pending.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website iba-worldwide.com.
Company details
Contact details
Curium Pharma (India) Private Limited's registered office is in Mumbai, Maharashtra. Its website is iba-worldwide.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address4/42 Tardeo A/C Market Building Tardeo Road, Mumbai, Maharashtra, India – 400034
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Curium Pharma (India) Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Curium Pharma (India) operates one associated brand: IBA. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Innovative solutions for cancer treatment and industrial applications are provided by IBA. | iba-worldwide.com |
Business activity
The main business activities of Curium Pharma (India) are manufacturing, trade and support service to organizations. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products, wholesale trading and other support services to organizations. 3 activity segments are registered with the MCA.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | |
| G | Trade | G1 | Wholesale Trading | |
| N | Support service to Organizations | N7 | Other support services to organizations |
To see the full business activity and turnover split of Curium Pharma (India) Private Limited, buy the company report.
Financials of Curium Pharma (India) Private Limited
FY 2025 filings availableCurium Pharma (India) Private Limited reported revenue of ₹41.38 Cr (down 3% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue fell 3% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 12%. EBITDA rose 13% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | ₹41.38 Cr | ||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹7.31 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹4.53 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 17.7% | ||||
| Net Profit Margin | 11% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Curium Pharma (India) Private Limited, buy the company report.
Board of directors of Curium Pharma (India) Private Limited
Curium Pharma (India) has 3 current directors and 15 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Xavier Anne J Defourt Also directs: Heron Health Private Limited | Director | 11 Nov 2020 | 5 Years 11 Months | Current |
| Mustafa Aydin Kucuk | Additional Director | 10 Mar 2026 | 0 Years 7 Months | Current |
| Susamoy Mishra | Director | 26 Feb 2024 | 2 Years 8 Months | Current |
Peer comparison
Curium Pharma (India) Private Limited is compared with the 7 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Pregio Pharma Private Limited | ₹41.7 Cr (FY 2024) | 34.0% | Chennai, Tamil Nadu, India | |||
| Strava Healthcare Private Limited | ₹41.58 Cr (FY 2025) | 115.0% | Ahmedabad, Gujarat, India | |||
| J M Healthcare Private Limited | ₹41.39 Cr (FY 2024) | 29.0% | Chandigarh, India | |||
| Curium Pharma (India) Private Limitedthis company | ₹41.38 Cr (FY 2025) | ₹4.53 Cr | 11% | -3.0% | 26 | Mumbai, Maharashtra, India |
| Vinuthana Chem Tech Private Limited | ₹41.25 Cr (FY 2025) | 6.0% | Hyderabad, Telangana, India | |||
| Stuck Chemicals Private Limited | ₹41.23 Cr (FY 2024) | 9.0% | New Delhi, Delhi, India | |||
| Relixir Pharmaceuticals Private Limited | ₹41.19 Cr (FY 2023) | 48.0% | Hyderabad, Telangana, India | |||
| Lenus Life Care Private Limited | ₹41.1 Cr (FY 2024) | -30.0% | Chamba Ghar, Himachal Pradesh, India |
To see the full peer comparison of Curium Pharma (India) Private Limited, buy the company report.
Auditor
Curium Pharma (India) Private Limited is audited by RKACA & Associates, LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| RKACA & Associates, LLP | FY 2023 | 014372N/N500004 |
Shareholding
The shareholding of Curium Pharma (India) Private Limited is on record for 5 financial years, the latest being FY 2022, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Curium Pharma (India) Private Limited, buy the company report.
Legal cases
Curium Pharma (India) Private Limited has 3 court cases on record: 2 filed by Curium Pharma (India), 1 filed against it. 1 case is pending and 2 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 2 | 0 | 0 |
| Supreme Court | 1 | 1 | 1 |
Cases on record (3 of 3)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, South, Delhi | Commercial suit | Filed by the company against Nayati Healthcare and Research NCR Private Limited | Disposed |
| Supreme Court | Appeal | Filed against the company by Commissioner of Central Excise | Pending |
| District court, Gautam Buddha Nagar, Uttar Pradesh | Civil suit | Filed by the company against M/S Shiva Enterprises | Disposed |
To see the full case history of Curium Pharma (India) Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Curium Pharma (India) Private Limited has 2 MSME Form 1 returns on record between 2019 and 2020, listing 2 overdue payments to 2 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (2 of 2)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| an individual supplier |
To see the full MSME payment records of Curium Pharma (India) Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Curium Pharma (India) Private Limited has a workforce of 26 employees on its EPFO records as of Mar 28, 2024, across 1 active EPFO establishment.
GST
Curium Pharma (India) has 3 GST registrations: 2 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 09AABCI3249R1ZZ | Uttar Pradesh | Active | 01 Jul 2017 |
| 03AABCI3249R1ZB | Punjab | Active | 12 Mar 2020 |
To see the full GST registrations and return filing status of Curium Pharma (India) Private Limited, buy the company report.
Recent activity
Curium Pharma (India) Private Limited has 17 board changes on record since 2009: 4 appointments and 13 cessations. The latest: Mustafa Aydin Kucuk was appointed as Additional Director on 10 Mar 2026.
8 earlier events are in the company report.
News
Frequently asked questions
Curium Pharma (India) is an active private limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 24 December 2004 (22+ years old) and is registered under CIN U24230MH2004PTC150212.
Curium Pharma (India) has 3 current directors:
- Xavier Anne J Defourt - Director
- Mustafa Aydin Kucuk - Additional Director
- Susamoy Mishra - Director
The latest financial statements of Curium Pharma (India) on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 22 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Curium Pharma (India) is 09AABCI3249R1ZZ, registered in Uttar Pradesh. The company has 3 GST registrations in all, of which 2 are active and 1 is cancelled or inactive. Other active GSTINs include 03AABCI3249R1ZB (Punjab).
The CIN (Corporate Identification Number) of Curium Pharma (India) is U24230MH2004PTC150212. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Curium Pharma (India) has 3 court cases on record: 2 filed by the company and 1 filed against it. 1 is pending. Most are in the district courts.
Curium Pharma (India) was incorporated on 24 December 2004, making it 22+ years old. It is registered with the Registrar of Companies, Mumbai.
The peers of Curium Pharma (India) by revenue are Pregio Pharma Private Limited, Strava Healthcare Private Limited, J M Healthcare Private Limited, Vinuthana Chem Tech Private Limited, Stuck Chemicals Private Limited and 2 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Mustafa Aydin Kucuk was appointed as Additional Director on 10 Mar 2026. Susamoy Mishra ceased to be Additional Director on 19 Sep 2024. Susamoy Mishra was appointed as Director on 26 Feb 2024. Curium Pharma (India) has 17 board changes on record in total.
Curium Pharma (India) has 2 MSME Form 1 returns on record between 2019 and 2020, listing 2 overdue payments to 2 micro and small suppliers. The latest return was filed on 06 Nov 2020.
Curium Pharma (India) can be reached through the website iba-worldwide.com. Its registered office is in Mumbai, Maharashtra, India.
The registered office of Curium Pharma (India) is at 442 Tardeo AC Market Building Tardeo Road, Mumbai, Maharashtra, India – 400034.